

# 参考文献 (続き)

- Henegar C, Underwood M, Ragone L, et al. Trends and characteristics of HIV-1 drug resistance in the United States (2012-2018). Program and abstracts of the 2020 Conference on Retroviruses and Opportunistic Infections. March 8-11, 2020. Boston, MA (Virtual). Abstract 521.
- Kozal M, Aberg J, Pialoux G, et al. Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection. *N Engl J Med*. 2020;382:1232-1243.
- Lataillade M, Zhou N, Joshi SR, et al. Viral drug resistance through 48 weeks, in a phase 2b, randomized, controlled trial of the HIV-1 attachment inhibitor prodrug, fostemsavir. *J Acquir Immune Defic Syndr*. 2018;77:299-307.
- Li Z, Zhou N, Sun Y, et al. Activity of the HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068, against CD4-independent viruses and HIV-1 envelopes resistant to other entry inhibitors. *Antimicrob Agents Chemother*. 2013;57:4172-4180.
- Margot N, et al. AIDS 2022. Abstract 240
- Martin EA, Lai J, Ngo W, et al. Review of Doravirine Resistance Patterns Identified in Participants During Clinical Development. *J Acquir Immune Defic Syndr*. 2020;85(5):635-642.
- Mazzuti L, Melengu T, Falasca F, et al. Transmitted drug resistance mutations and trends of HIV-1 subtypes in treatment-naïve patients: A single-centre experience. *J Glob Antimicrob Resist*. 2020;20:298-303.
- McClung RP, Oster AM, Bañez Ocfemia MC, et al. Transmitted Drug Resistance Among HIV-1 Diagnoses in the United States, 2014-2018. *Clin Infect Dis*. 2021. Online ahead of print.
- McGee KS, Okeke NL, Hurt CB, et al. Canary in the Coal Mine? Transmitted Mutations Conferring Resistance to All Integrase Strand Transfer Inhibitors in a Treatment-Naïve Patient. *Open Forum Infect Dis*. 2018;5(11):ofy294.
- McGovern RA, Thielen A, Mo T, et al. Population-based V3 genotypic tropism assay: A retrospective analysis using screening, samples from the A4001029 and MOTIVATE studies. *AIDS*. 2010;24:2517-2525.
- Miller V. International perspectives on antiretroviral resistance. Resistance to protease inhibitors. *J Acquir Immune Defic Syndr*. 2001;26 Suppl 1:S34-S50.
- Miranda MNS, Pingarilho M, Pimental V. et al. Resistance in Europe from 1981 to 2019: A Comparison Between the Populations of Late Presenters and Non-Late Presenters. *Frontiers in Microbiology*. 2022; 13 . 13:846943. doi: 10.3389/fmicb.2022.846943